Czech patient with lung adenocarcinoma with the BRAF V600E mutation succesfully treated with dabrafenib plus trametinib
2021
Abstract
Targeted therapy has improved the prognosis of patients with non-small-cell lung carcinoma. New targets of treatment include the BRAF V600E mutation.
Probably the first case of a succesfully treated Czech patient is discussed in this case report. A 39-year-old man was first treated with cisplatin plus pemetrexed chemotherapy.
After two cycles, targeted treatment was approved by his health insurance company. Therefore, therapy with dabrafenib plus trametinib was initiated.
The patient has tolerated the treatment very well; no side effects have occurred so far. A partial response was documented by a CT scan after six months of treatment.